BSX stock: buy or sell?
August 19th, 2019
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
Should I buy BSX stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Boston Scientific stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Boston Scientific stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we collected 12 ratings published for BSX stock in the last 30 days. The general sentiment of these ratings is bullish for BSX stock, with 9 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-6-27||Piper Jaffray Companies||n/a||Overweight|
|2019-6-27||Jefferies Financial Group||Buy||Positive|
|2019-6-18||Wells Fargo & Co||n/a||Outperform|
|2019-2-6||Needham & Company LLC||n/a||Buy|
|2019-1-8||Needham & Company LLC||n/a||Buy|
BSX stock analysis
Boston Scientific closed today at $42.73 and appreciated a decent 1.38%.
Boston Scientific closed today at $42.73 and appreciated a decent 1.38%. On May BSX price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. Since SMA50d and SMA100d crossed up on July, BSX price slid a -0.40%.
Shares of Boston Scientific closed this week at $42.73 and stepped up a tiny 1.38%.
BSX marked an uptrend of rising tops and rising bottoms. Since its last top early July at $43.66, price slid and bounced up back from $40.91. Breaking down under $40.91 would cancel the current uptrend and it might test lower supports. Note that $43.66 might act as a resistance line. By mid May BSX price bounced up over the SMA of 40 weeks that acted as support stopping new slides. Since late June when SMA10w and SMA20w crossed up, BSX price gained $1.04 per share (2.49%).
BSX stock price history
BSX stock went public on May 19th, 1992 with a price of $4.251. Since then, BSX stock grew a 905.40%, with an average of 33.50% per year. If you had invested right after BSX's IPO a $1,000 in BSX stock in 1992, it would worth $9,054.00 today.
1: Adjusted price after possible price splits or reverse-splits.
BSX stock historical price chart
BSX stock reached 52-week highs on July at $43.66, and all-time highs 2004-04-06 with a price of 46.1.
BSX stock price target is $46.30Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 12 price forecasts for Boston Scientific stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-25||Raymond James||Raises Target||$48.00||$50.00||4.2%|
|2019-6-27||Piper Jaffray Companies||Raises Target||$42.00||$50.00||19%|
|2019-6-27||Jefferies Financial Group||Raises Target||$44.00||$48.00||9.1%|
|2019-6-18||Wells Fargo & Co||Raises Target||$42.00||$45.00||7.1%|
|2019-2-6||Needham & Company LLC||Reiterates||n/a||$43.00||-|
|2019-1-8||Needham & Company LLC||Reiterates||n/a||$43.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareBoston Scientific presented slightly good results for 2018-Q4 on February. Boston Scientific raised Earnings per Share (EPS) by 5.40%, beating analysts estimates of $0.37. Boston Scientific posted $0.39.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Boston Scientific annual sales rose a very good 8.57% to $9,823.00 million dollars from $9,048.00 marked in 2017. When comparing 2018 vs 2017, in the same way, profit margin (that is, the net income divided by revenues) climbed a 15.86% to 17.01%.
|2013||$7,140 M||-||$-121.00 M-1.7%||-|
|2014||$7,380 M||3.36%||$-119.00 M-1.6%||-1.65%|
|2015||$7,477 M||1.31%||$-239.00 M-3.2%||100.84%|
|2016||$8,386 M||12.16%||$347 M4.1%||-245.19%|
|2017||$9,048 M||7.89%||$104 M1.1%||-70.03%|
|2018||$9,823 M||8.57%||$1,671 M17.0%||1,506.73%|
Quarterly financial resultsBoston Scientific reported $2,561.00 M in revenues for 2018-Q4, a 7.02% improvement compared to previous quarter. Reported quarter income marked $386.00 million with a profit margin of 15.07%. Profit margin decreased a -2.98% compared to previous quarter when profit margin was 18.05%. When comparing turnover to same quarter last year, Boston Scientific sales marked a remarkable gain and soared a 6.35%.
|2017-Q2||$2,260 M||-||$146 M6.5%||-|
|2017-Q3||$2,220 M||-1.77%||$283 M12.7%||93.84%|
|2017-Q4||$2,408 M||8.47%||$-615 M-25.5%||-317.31%|
|2018-Q1||$2,379 M||-1.20%||$298 M12.5%||-148.46%|
|2018-Q2||$2,490 M||4.67%||$555 M22.3%||86.24%|
|2018-Q3||$2,393 M||-3.90%||$432 M18.1%||-22.16%|
|2018-Q4||$2,561 M||7.02%||$386 M15.1%||-10.65%|
|2019-Q1||$2,493 M||-2.66%||$424 M17.0%||9.84%|
Boston Scientific ownershipWhen you are planning to invest in a company, it's worth to have a look its ownership structure.
Boston Scientific shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.25% of all shares.
Bearish positions for BSX stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related companies:
|Market cap||$59.4 B||$707.2 M||$2.7 B||$45.6 B||$0.0 M|
|Total shares||1,390.0 M||37.3 M||28.3 M||208.1 M||0.0 M|
|Float shares||1,390.0 M||36.8 M||27.6 M||206.6 M||1,340.0 M|
|- Institutional holdings (%)||93.4%||102.5%||97.5%||0.0%||84.2%|
|- Insider holdings (%)||0.2%||2.5%||1.8%||3.9%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Monday, August 19th, 2019|
|Day range||$42.45 - $43.07|
|Average true range||$1.08|
|50d mov avg||$42.16|
|100d mov avg||$39.86|
|200d mov avg||$38.55|
Boston Scientific performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared Boston Scientific against AngioDynamics, CONMED, Edwards Lifesciences, Medtronic, Merit Medical Systems, Stryker and Teleflex in the following table:
|MMSIMerit Medical Sys...||-34.09%||-39.30%||-36.13%|
Boston Scientific competitorsOne check before trading any stock is to review a list of its competitors, in this case for Boston Scientific. We chose 7 companies as Boston Scientific competitors as they are in the same industry or have similar market objectives.
- AngioDynamics (ANGO)
- CONMED (CNMD)
- Edwards Lifesciences (EW)
- Medtronic (MDT)
- Merit Medical Systems (MMSI)
- Stryker (SYK)
- Teleflex (TFX)
Latest BSX stock news
- Seeking AlphaBoston Scientific: A Diversified Portfolio With Growth ProspectsJuly 11, 2019
- InvestorPlace3 Big Stock Charts for Tuesday: Centene, Boston Scientific and Hewlett Packard EnterpriseMay 28, 2019
- Seeking AlphaBoston Scientific: New-Found Profitability After A Decade Of VolatilityMarch 22, 2019
- InvestorPlace3 Big Stock Charts for Thursday: FirstEnergy, Boston Scientific and MondelezFebruary 7, 2019
- InvestorPlace3 Stock Charts for Monday: Gap, CenterPoint Energy and Boston ScientificJanuary 7, 2019